Wells S, Malik P, Pensiero M, Kohn D B, Nolta J A
Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital Los Angeles, CA 90027, USA.
Gene Ther. 1995 Oct;2(8):512-20.
Gaucher disease is a lysosomal storage disorder resulting form deficiency of the acid beta-glucosidase, glucocerebrosidase (GC). Allogeneic bone marrow transplantation has been beneficial in the treatment of Gaucher patients. Therefore, this disorder may be an ideal candidate for gene therapy by GC gene transduction of hematopoietic stem cells. We sought to increase the extent of gene transfer into CD34+ cells from the marrow of a Gaucher patient using G1GC, a simple retroviral vector containing a normal human GC cDNA. The ability of autologous stromal support and recombinant cytokines to increase the extent of transduction of colony-forming-cells (CFCs) and long-term culture initiating cells (LTCICs) was assessed. The presence of a stromal layer significantly increased the extent of GC gene transfer into 14-day CFCs, as determined by polymerase chain reaction (PCR) of individual colonies (18.8% with stroma versus 5% without, P < 0.001). Stromal support also increased the extent of transduction of LTCICs (10% with stroma versus 0.83% without, P < 0.001). Non-adherent cells from long-term bone marrow cultures initiated with CD34+ progenitors transduced on autologous stroma had higher levels of GC enzyme activity than cultures initiated with cells transduced without stroma. The percentage of cells which were GC positive by immunohistochemistry was also increased (21.1% with stroma versus 2.7% without, P = 0.0003). The addition of cytokines (IL-3, IL-6 and Steel factor) to the transduction, in the presence of stroma, significantly increased the extent of gene transfer into CFCs but not LTCICs. These studies indicate that the GC gene can be effectively transduced into LTCICs by retroviral vectors in the presence of stroma at levels significant for clinical gene therapy trials in patients with Gaucher disease.
戈谢病是一种溶酶体贮积症,由酸性β-葡萄糖苷酶(葡糖脑苷脂酶,GC)缺乏所致。同种异体骨髓移植对戈谢病患者的治疗有益。因此,这种疾病可能是通过造血干细胞的GC基因转导进行基因治疗的理想候选对象。我们试图使用G1GC(一种含有正常人GC cDNA的简单逆转录病毒载体)来提高从一名戈谢病患者骨髓中分离出的CD34+细胞的基因转移程度。评估了自体基质支持和重组细胞因子增加集落形成细胞(CFC)和长期培养起始细胞(LTCIC)转导程度的能力。通过对单个集落进行聚合酶链反应(PCR)测定,基质层的存在显著提高了GC基因向14天CFC的转移程度(有基质时为18.8%,无基质时为5%,P<0.001)。基质支持也提高了LTCIC的转导程度(有基质时为10%,无基质时为0.83%,P<0.001)。在自体基质上转导的CD34+祖细胞起始的长期骨髓培养中的非贴壁细胞,其GC酶活性水平高于无基质转导细胞起始的培养物。通过免疫组织化学检测为GC阳性的细胞百分比也增加了(有基质时为21.1%,无基质时为2.7%,P = 0.0003)。在有基质存在的情况下,转导时添加细胞因子(IL-3、IL-6和Steel因子)可显著提高基因向CFC的转移程度,但对LTCIC无此作用。这些研究表明,在有基质存在的情况下,逆转录病毒载体可将GC基因有效转导至LTCIC,其水平对戈谢病患者的临床基因治疗试验具有重要意义。